SIOX — Sio Gene Therapies Share News
0.000.00%
Last trade - 00:00Sio Gene up on FDA fast track tag for rare disease drug
Brief: Sio Gene Therapies Announces Granting Of FDA Fast Track Designation For Investigational Axo-Aav-Gm2 Gene Therapy
Brief: Sio Gene Therapies Announces Granting Of FDA Fast Track Designation
Brief: Sio Gene Therapies Announces Positive Interim Safety And Biomarker Data From Ongoing Phase 1/2 Clinical Study Of AXO-AAV-GM1 Gene Therapy In GM1 Gangliosidosis
Brief: Sio Gene Therapies Announces Dosing Of First GM1 Gangliosidosis Early Infantile Patient In Ongoing Phase 1/2 Study Of AXO-AAV-GM1 Gene Therapy
Sio Gene Therapies Inc reports results for the quarter ended in June - Earnings Summary
Brief: Sio Gene Therapies Q1 Loss Per Share $0.16
'Looking for upside in biotech? Start with gene therapy' - BTIG
Sino Gene surges as BTIG sees promise in co's gene therapy trials
U.S. RESEARCH ROUNDUP-Eli Lilly, Physicians Realty Trust, Welltower
Brief: Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results And Expected Fiscal Year 2021 Key Milestones
Brief: Sio Gene Therapies Posts Q3 Loss Per Share $0.20
Brief: Sio Gene Therapies Announces Receipt Of $11.6 Million From Closing Of The Sale Of Arvelle Therapeutics
Brief: Sio Gene Therapies Announces First Patient Dosed In Clinical Trial Of AXO-AAV-GM2 In Patients With Tay-Sachs And Sandhoff Disease
Brief: Sio Gene Therapies To Sell Arvelle Stake As Part Of Angelini Pharma’S Acquisition Of Arvelle Therapeutics
U.S. STOCKS ON THE MOVE-Arvinas, BioCardia, Hexindai
Brief: Sio Gene Therapies Inc Files For Offering Of Up To $100 Million Of Common Stock - SEC Filing
Sio Gene: Surges on positive follow-up data from gene therapy study
Brief: Sio Gene Therapies Announces Positive Six-Month Follow-Up Data From Low-Dose Cohort Of Phase 1/2 Trial Of Axo-Aav-Gm1 For Gm1 Gangliosidosis